论文信息 - Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients - 字舞流文

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

C. Charpentier | G. Carcelain | C. Delaugerre | J. Pawlotsky | T. Naas | S. Burrel | F. Rozenberg | M. Rameix-Welti | D. Descamps | I. Podglajen | C. Alloui | N. Houhou-Fidouh | S. Bonacorsi | M. Chaix | E. Gordien | E. Gault | V. Avettand-Fenoel | S. Fourati | F. Damond | L. Morand‐Joubert | M. Leruez-Ville | L. Dortet | A. Marcelin | D. Challine | S. Maylin | S. Akhavan | J. Legoff | H. Petit | N. Boukli | J. Gozlan | J. Fourgeaud | S. Marot | J. Meritet | C. Périllaud-Dubois | Samuel Lepape | S. Brichler | Jean-Baptiste Ronat | V. Mackiewicz | F. Moreau | A. Carol | E. Gardiennet | J. Villemonteix | T. Guilleminot | C. Vauloup-fellous | A. Roque-Afonso | C. Vauloup‐Fellous

[1] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[2] G. Rodger,et al. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.

[3] Y. Yazdanpanah,et al. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations , 2020, Science Translational Medicine.

[4] Mark S. Anderson,et al. Test performance evaluation of SARS-CoV-2 serological assays , 2020, Nature biotechnology.

[5] G. Natoli,et al. Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers , 2020, medRxiv.

[6] M. Koopmans,et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment , 2020, Nature Communications.

[7] C. Bethel,et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies , 2020, bioRxiv.

[8] S. Yerly,et al. Validation of a commercially available SARS-CoV-2 serological immunoassay , 2020, Clinical Microbiology and Infection.

[9] D. Cummings,et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease , 2020, medRxiv.

[10] Y. Yazdanpanah,et al. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[11] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[12] Jonathan E. Schmitz,et al. Laboratory Diagnosis of COVID-19: Current Issues and Challenges , 2020, Journal of Clinical Microbiology.

[13] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[14] T. Palaga,et al. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.

[15] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[16] Wei Zhang,et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes , 2020, Emerging microbes & infections.

[17] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.